Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discusses the findings of a landmark survivorship study (Abstract LBA2).
Lisa Diller, MD, of Dana-Farber Cancer Institute, and Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discuss the findings of a landmark survivorship study (Abstract LBA2).
James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain genetic abnormalities for which a targeted drug exists.
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).
